Inato, a marketplace that helps biopharmaceutical companies increase the pool of available patients engaged in clinical trials, has unveiled its anticovid platform, a comprehensive, central repository for all existing clinical trials for SARS-CoV 2 (the virus that causes COVID-19).
Epidemiological data suggests populations with the highest measles-mumps-rubella (MMR) vaccination rates often have the fewest deaths from COVID-19.
The Centers for Medicare and Medicaid Services (CMS) has broadened access to Medicare telehealth services so beneficiaries can receive a wider range of services from their doctors without having to travel to a healthcare facility.
The U.S. Food and Drug Administration (FDA) has launched a campaign to help consumers use the new Nutrition Facts label that appears on packaged foods to maintain healthy dietary practices.
In March, the U.S. Department of Health and Human Services (HHS) finalized two rules that give patients unprecedented safe and secure access to their health data.
The U.S. Department of Health and Human Services (HHS) is using a $100 billion hospital and provider relief fund to pay hospitals at Medicare rates for uncompensated COVID-19 care for uninsured individuals.
Sandoz has announced that the citrate-free high-concentration formulation of its biosimilar Hyrimoz (adalimumab-adaz) injection became available in the United States starting July 1, 2023.
Efgartigimod, an investigational human IgG1 Fc fragment, induced a rapid reduction in total IgG levels and clinically relevant increases in platelet counts in patients with primary immune thrombocytopenia (ITP), according to findings from a Phase II, placebo-controlled multinational study.
A study in previously untreated patients (PUPs) with severe hemophilia A found replacement therapy with a fourth-generation recombinant factor VIII (FVIII) product was associated with an incidence of high-titer inhibitors similar to the rate seen in a landmark trial evaluating plasma-derived FVIII products.
Two analyses by the Centers for Disease Control and Prevention (CDC) show the influenza (flu) vaccine can reduce the likelihood of hospitalization in children and death in adults.
A Phase III study has found a trivalent hepatitis B virus (HBV) vaccine demonstrated superiority in adults 45 years and older and noninferior in adults older than 18 years compared with a monovalent vaccine.
Researchers have found combining immune tolerance induction (ITI) with Hemlibra (emicizumab, Roche) is a feasible and safe way of treating children with severe hemophilia A.